Role of VEGF/VEGFR in the pathogenesis o leukemias and as treatment targets (Review)

Oncology Reports

Volumn 28, Issue 6, 2012, Pages 1935-1944

  Song, Guanhua ^a   Li, Yanmei ^a   Jiang, Guosheng ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Antiangiogenesis; Leukemia; Vascular endothelial growth factor; Vascular endothelial growth factor receptor

Indexed keywords

ANGIOGENESIS INHIBITOR; AZACITIDINE; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CYTARABINE; DAUNORUBICIN; FIBROBLAST GROWTH FACTOR; FLUDARABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IDARUBICIN; IMATINIB; LENALIDOMIDE; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR; STRESS ACTIVATED PROTEIN KINASE; SUNITINIB; THALIDOMIDE; TOPOTECAN; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL PERMEABILITY; BONE MARROW BIOPSY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CORRELATION ANALYSIS; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GRANULOCYTIC SARCOMA; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LEUKEMOGENESIS; LIVER CELL CARCINOMA; MOLECULAR DYNAMICS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; LEUKEMIA; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84868099470     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2045     Document Type: Conference Paper

References (118)

1. Kerbel RS: Tumor angiogenesis. N Engl J Med 358:2039-2049, 2008. (Pubitemid 351656458)
2. Ellis LM and Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591, 2008.
3. Medinger M, Fischer N and Tzankov A: Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. J Oncol 2010:729725, 2010. doi: 10.1155/2010/729725.
4. Aguayo A, Kantarjian HM, Estey EH, et al: Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 95:1923-1930, 2002. (Pubitemid 35222172)
5. Zhu Z, Hattori K, Zhang H, et al: Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 17:604-611, 2003. (Pubitemid 36395655)
6. Benouchan M and Colombo BM: Anti-angiogenic strategies for cancer therapy. Int J Oncol 27:563-571, 2005.
7. Ferrara N and Henzel WJ: Pituitary follicular cell secrete a novel heparin-binding growth factor specific for vascular endothelial cell. Biochem Biophys Res Commun 161:851, 1989.
8. Ferrara N, Gerber HP and Le Couter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003. (Pubitemid 36749215)
9. Cao Y: Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2:re1, 2009.
10. Zhang L, Zhou F, Han W, et al: VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis. Cell Res 20:1319-1331, 2010.
11. Wu Y, Hooper AT, Zhong Z, et al: The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 119:1519-1529, 2006. (Pubitemid 44258756)
12. Autiero M, Luttun A, Tjwa M and Carmeliet P: Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 1:1356-1370, 2003.
13. Holmes K, Roberts OL, Thomas AM and Cross MJ: Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19:2003-2012, 2007. (Pubitemid 47354167)
14. Brekken RA, Overholser J P, Stastny VA, Waltenberger J, Minna JD and Thorpe PE: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60:5117-5124, 2000.
15. Katoh O, Tauchi H, Kawaishi K, Kimura A and Satow Y: Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 55:5687-5692, 1995.
16. Cursiefen C, Chen L, Borges LP, et al: VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 113:1040-1050, 2004. (Pubitemid 38544126)
17. Adams J, Carder PJ, Downey S, et al: Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 60:2898-2905, 2000. (Pubitemid 30395813)
18. Kay NE, Bone ND, Tschumper RC, et al: B-CLL cells are capable of synthesis and secretion of both pro-and anti-angiogenic molecules. Leukemia 16:911-919, 2002. (Pubitemid 34537565)
19. Rafii S, Lyden D, Benezra R, Hattori K and Heissig B: Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826-835, 2002. (Pubitemid 37328901)
20. Shweiki D, Itin A, Soffer D and Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845, 1992.
21. Dor Y, Porat R and Keshet E: Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 280:C1367-C1374, 2001. (Pubitemid 32553191)
22. Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13:680s-682s, 2007. (Pubitemid 46220084)
23. Cong XL, Li B, Yang RC, Feng SZ, Chen SJ and Han ZC: Enhanced growth suppression of Philadephia1 leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy. Leukemia 19:1517-1524, 2005. (Pubitemid 43090393)
24. Ghosh AK, Shanafelt TD, Cimmino A, et al: Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 113:5568-5574, 2009.
25. Withey JM, Marley SB, Kaeda J, Harvey AJ, Crompton MR and Gordon MY: Targeting primary human leukemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells. Br J Haematol 129:377-380, 2005. (Pubitemid 40646897)
26. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc 3:1101-1108, 2008. (Pubitemid 351818697)
27. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D and Kay NE: Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 115:1755-1764, 2010.
28. Aggarwal BB, Sethi G, Ahn KS, et al: Targeting signaltransducer-and- activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann NY Acad Sci 1091:151-169, 2006. (Pubitemid 47092233)
29. Eriksen KW, Kaltoft K, Mikkelsen G, et al: Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 15:787-793, 2001. (Pubitemid 32492702)
30. Nielsen M, Nissen MH, Gerwien J, et al: Spontaneous interleuk in-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3. Blood 99:973-977, 2002. (Pubitemid 34525560)
31. Minet E, Michel G, Mottet D, et al: c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp Cell Res 265:114-124, 2001. (Pubitemid 32989069)
32. Pages G, Berra E, Milanini J, Levy AP and Pouyssegur J: Stressactivated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 275:26484-26491, 2000.
33. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, et al: Jak3-and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 20:1759-1766, 2006. (Pubitemid 44574987)
34. Kumar SA, Hu X, Brown M, et al: Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression. Leuk Lymphoma 50:2038-2048, 2009.
35. Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB and Gibson SB: Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cell Signal 20:1198-1208, 2008.
36. Aguayo A, Kantarjian H, Manshouri T, et al: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96:2240-2245, 2000.
37. Bellamy W T, Richter L, Sirjani D, et al: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97:1427-1434, 2001. (Pubitemid 32183769)
38. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P and Kroemer G: Targeting NF-kappaB in hematologic malignancies. Cell Death Differ 13:748-758, 2006.
39. Zhao T, Yasunaga J, Satou Y, et al: Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood 113:2755-2764, 2009.
40. Sujobert P, Bardet V, Cornillet-Lefebvre P, et al: Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 106:1063-1066, 2005. (Pubitemid 41076455)
41. Ramos AM, Fernandez C, Amran D, Sancho P, De Blas E and Aller P: Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 105:4013-4020, 2005. (Pubitemid 40656150)
42. Shi Q, Le X, Abbruzzese JL, et al: Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61:4143-4154, 2001. (Pubitemid 32720983)
43. Hsu TC, Young MR, Cmarik J and Colburn NH: Activator protein 1 (AP-1) and nuclear factor kappaB (NF-kappa B)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 28:1338-1348, 2000. (Pubitemid 30621478)
44. Angel P and Karin M: The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1072:129-157, 1991. (Pubitemid 121007534)
45. Pollmann C, Huang X, Mall J, Bech-Otschir D, Naumann M and Dubiel W: The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells. Cancer Res 61:8416-8421, 2001. (Pubitemid 33131118)
46. Poulaki V, Mitsiades CS, McMullan C, et al: Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab 88:5392-5398, 2003. (Pubitemid 37452744)
47. Chuang CH, Huang CS and Hu ML: Vitamin E and rutin synergistically inhibit expression of vascular endothelial growth factor through down-regulation of binding activity of activator protein-1 in human promyelocytic leukemia (HL-60) cells. Chem Biol Interact 183:434-441, 2010.
48. Rho SB, Choi K, Park K and Lee JH: Inhibition of angiogenesis by the BTB domain of promyelocytic leukemia zinc finger protein. Cancer Lett 294:49-56, 2010.
49. Konopka JB, Watanabe SM and Witte ON: An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035-1042, 1984. (Pubitemid 15139294)
50. Pendergast AM, Quilliam LA, Cripe LD, et al: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175-185, 1993. (Pubitemid 23306031)
51. Carlesso N, Frank DA and Griffin JD: Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 183:811-820, 1996. (Pubitemid 26113953)
52. Sillaber C, Gesbert F, Frank DA, Sattler M and Griffin JD: STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 95:2118-2125, 2000. (Pubitemid 30151654)
53. Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B and Skorski T: Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Src homology (SH) 3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 189:1229-1242, 1999. (Pubitemid 29198261)
54. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, et al: Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16:6151-6161, 1997. (Pubitemid 27458335)
55. Hwan D, Kim, Xu W, et al: Lipton genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Blood 113:2517-2525, 2009.
56. Li L, Zhang R, Fang ZY, Chen JN and Zhu ZL: Suppression of vascular endothelial growth factor (VEGF) expression by targeting the Bcr-Abl oncogene and protein tyrosine kinase activity in Bcr-Abl-positive leukaemia cells. J Int Med Res 37:426-437, 2009.
57. Böhm A, Aichberger KJ, Mayerhofer M, et al: Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells. Eur J Clin Invest 39:395-405, 2009.
58. Venables JP: Unbalanced alternative splicing and its significance in cancer. Bioessays 28:378-386, 2006.
59. Podar K, Tai YT and Davies FE: Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98:428-435, 2001.
60. Hussong JW, Rodgers GM and Shami PJ: Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95:390-313, 2000.
61. Padró T, Ruiz S, Bieker R, Bürger H, Steins M, Kienast J, et al: Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95:2637-2644, 2000. (Pubitemid 30210544)
62. Abrams ST, Lakum T, Lin K, et al: B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CβII. Blood 109:1193-1201, 2007. (Pubitemid 46220668)
63. Gora-Tybor J, Blonski JZ and Robak T: Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. Eur Cytokine Netw 16:41-46, 2005. (Pubitemid 40478075)
64. Abrams ST, Brown BR, Zuzel M and Slupsky JR: Vascular endothelial growth factor stimulates protein kinase CβII expression in chronic lymphocytic leukaemia cells. Blood 115:4447-4454, 2010.
65. Ugarte-Berzal E, Redondo-Muñoz J, Eroles P, et al: VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration. Blood 115:846-849, 2010.
66. Hata AN and Breyer RM: Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 103:147-166, 2004. (Pubitemid 39209041)
67. Wu G, Luo J, Rana JS, Laham R, Sellke FW and Li J: Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc 69:512-519, 2006. (Pubitemid 43098807)
68. Su JL, Shih JY, Yen ML, et al: Cyclooxygenase-2 induces EP1-and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 64:554-564, 2004.
69. Véronèse L, Tournilhac O, Verrelle P, et al: Low MCL-1 mRNA expression correlates with prolonged survival in B-cell chronic lymphocytic leukemia. Leukemia 22:1291-1293, 2008. (Pubitemid 351833810)
70. Pepper C, Lin TT, Pratt G, et al: Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 112:3807-3817, 2008.
71. Véronèse L, Tournilhac O, Verrelle P, et al: Strong correlation between VEGF and MCL-1 mRNA expression levels in B-cell chronic lymphocytic leukemia. Leuk Res 33:1623-1626, 2009.
72. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E and Folkman J: Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150:815-821, 1997. (Pubitemid 27106153)
73. Yetgin S, Yenicesu I, Etin MC and Tuncer M: Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma 42:83-88, 2001. (Pubitemid 32700925)
74. Dong X, Han ZC and Yang R: Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol 62:105-118, 2007. (Pubitemid 46584811)
75. Frater JL, Kay NE, Goolsby CL, Crawford SE, Dewald GW and Peterson LC: Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence. Diagn Pathol 3:16, 2008.
76. Norén-Nyström U, Heyman M, Frisk P, et al: Vascular density in childhood acute lymphoblastic leukaemia correlates to biological factors and outcome. Br J Haematol 146:521-530, 2009.
77. Chen H, Treweeke AT, West DC, Till KJ, Cawley JC, Zuzel M and Toh CH: In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 96:3181-3187, 2000.
78. Folkman J: Fundamental concepts of the angiogenic process. Curr Mol Med 3:643-651, 2003. (Pubitemid 37236406)
79. Verstovsek S, Lunin S, Kantarjian H, et al: Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res 27:661-669, 2003. (Pubitemid 36398103)
80. Hayashibara T, Yamada Y, Miyanishi T, et al: Vascula r endothelial growth factor and cellular chemotaxis: a possible autocrine pathway in adult T-cell leukemia cell invasion. Clin Cancer Res 7:2719-2726, 2001. (Pubitemid 32911376)
81. Demacq C, Vasconcellos VB, Izidoro-Toledo TC, et al: Vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (NOS3) polymorphisms are associated with high relapse risk in childhood acute lymphoblastic leukemia (ALL). Clin Chim Acta 411:1335-1405, 2010.
82. Fragoso R, Elias AP and Dias S: Autocrine VEGF loops, signaling pathways, and acute leukemia regulation. Leuk Lymphoma 48:481-488, 2007. (Pubitemid 46487754)
83. Bellamy WT: Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 28:551-559, 2001. (Pubitemid 33134414)
84. Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M and Rabizadeh E: All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res 28:243-248, 2004. (Pubitemid 37550058)
85. De Bont ES, Neefjes VM, Rosati S, Vellenga E and Kamps WA: New vessel formation and aberrant VEGF/VEGFR signaling in acute leukemia: does it matter? Leuk Lymphoma 43:1901-1909, 2002.
86. Aguayo A, Estey E, Kantarjian H, et al: Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94:3717-3721, 1999.
87. Fu J, Fu J, Chen X, Zhang Y, Gu H and Bai Y: CD147 and VEGF co-expression predicts prognosis in patients with acute myeloid leukemia. Jpn J Clin Oncol 40:1046-1052, 2010.
88. Fiedler W, Graeven U, Ergün S, et al: Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89:1870-1875, 1997. (Pubitemid 27132100)
89. Koistinen P, Siitonen T, Mäntymaa P, et al: Regulation of the acute myeloid leukemia cell line OCI/AML-2 by endothelial nitric oxide synthase under the control of a vascular endothelial growth factor signaling system. Leukemia 15:1433-1441, 2001. (Pubitemid 32785313)
90. Fielder W, Graeven U, Ergün S, et al: Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia 11:1234-1237, 1997. (Pubitemid 27387298)
91. De Jonge HJ, Valk PJ, Veeger NJ, et al: High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 116:1747-1754, 2010.
92. Molica S, Vitelli G, Levato D, Gandolfo GM and Liso V: Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 107:605-610, 1999.
93. Ferrajoli A, Manshouri T, Estrov Z, et al: High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 7:795-799, 2001. (Pubitemid 32708712)
94. Dias S, Hattori K, Zhu Z, et al: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106:511-521, 2000. (Pubitemid 30666384)
95. Dias S, Hattori K, Heissig B, et al: Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 98:10857-10862, 2001. (Pubitemid 32878709)
96. Schuch G, Machluf M, Bartsch G Jr, et al: In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 100:4622-4628, 2002. (Pubitemid 35429707)
97. Liu P, Wang Y, Li YH, et al: Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leuk Res 27:701-708, 2003. (Pubitemid 36683259)
98. Vecchiarelli-Federico LM, Cervi D, Haeri M, Li Y, Nagy A and Ben-David Y: Vascular endothelial growth factor - a positive and negative regulator of tumor growth. Cancer Res 70:863-867, 2010.
99. Cervi D, Shaked Y, Haeri M, et al: Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia. Blood 109:2139-2146, 2007. (Pubitemid 46348216)
100. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239, 2009.
101. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004. (Pubitemid 38702844)
102. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006. (Pubitemid 44917502)
103. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007.
104. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007. (Pubitemid 46089673)
105. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007. (Pubitemid 46089672)
106. Karp JE, Gojo I, Pili R, et al: Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-β-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 10:3577-3585, 2004. (Pubitemid 38697590)
107. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997. (Pubitemid 27441066)
108. D'Amato RJ, Loughnan MS, Flynn E and Folkman J: Tha lidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085, 1994.
109. Teo SK: Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 7:E14-E19, 2005. (Pubitemid 41554303)
110. Dredge K, Marriott JB, Macdonald CD, et al: Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87:1166-1172, 2002. (Pubitemid 35418112)
111. Thomas DA, Estey E, Giles FJ, et al: Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol 123:436-441, 2003. (Pubitemid 37363483)
112. Steins MB, Padró T, Bieker R, et al: Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 99:834-839, 2002. (Pubitemid 34525543)
113. Barr P, Fu P, Lazarus H, et al: Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin and topotecan for high-risk acute myelogenous leukemia. Leuk Lymphoma 48:1940-1949, 2007. (Pubitemid 47542980)
114. Drevs J, Müller-Driver R, Wittig C, et al: PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62:4015-4022, 2002. (Pubitemid 34791068)
115. Roboz GJ, Giles FJ, List AF, et al: Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 20:952-957, 2006. (Pubitemid 43797284)
116. Wedge SR, Kendrew J, Hennequin LF, et al: AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400, 2005. (Pubitemid 40775678)
117. Fiedler W, Mesters R, Heuser M, et al: An open-label, phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Leuk Res 34:196-202, 2010.
118. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S and Galili N: Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 113:1596-1604, 2008.